Concise Synthesis of a Probe Molecule Enabling Analysis and Imaging of Vizantin
-
- Yamamoto Hirofumi
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Oda Masataka
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Nakano Mayo
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Yabiku Kenta
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Shibutani Masahiro
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Nakanishi Toshiyuki
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Suenaga Midori
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Inoue Masahisa
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Imagawa Hiroshi
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Nagahama Masahiro
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Matsunaga Yoichi
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Himeno Seiichiro
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Setsu Kojun
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Sakurai Jun
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
-
- Nishizawa Mugio
- Faculty of Pharmaceutical Sciences, Tokushima Bunri University
この論文をさがす
抄録
Trehalose 6,6′-dicorynomycolate (TDCM) was first characterized in 1963 as a cell surface glycolipid of Corynebacterium spp. by Ioneda and co-workers. TDCM shows potent anti-tumor activity due to its immunoadjuvant properties. Furthermore, the toxicity of TDCM in mice is much weaker than the related trehalose diester of mycolic acid; trehalose 6,6′-dimycolate (TDM, formerly known as cord factor). We have investigated the chemical modification of this class of compound to generate novel agents that display increased immunoadjuvant activity with minimal associated toxicity. During the course of this work we recently developed 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′-trehalose (designated as vizantin). Our results show that vizantin exhibited a potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells without a loss of body weight and death in mice. Furthermore, vizantin effectively stimulated human macrophages in an in vitro model, making it a promising candidate for a safe adjuvant in clinical applications. In order to elucidate the pharmacokinetics of vizantin, a probe molecule with similar activity was developed on the basis of a structure–activity relationship (SAR) study with vizantin. The distribution of the probe molecule after intravenous administration into a mouse was assessed by macro confocal microscopy, where it was found to accumulate in the lungs and liver.
収録刊行物
-
- CHEMICAL & PHARMACEUTICAL BULLETIN
-
CHEMICAL & PHARMACEUTICAL BULLETIN 61 (4), 452-459, 2013
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001204176644480
-
- NII論文ID
- 130003360757
-
- NII書誌ID
- AA00602100
-
- COI
- 1:STN:280:DC%2BC3srhtlOksg%3D%3D
-
- ISSN
- 13475223
- 00092363
-
- NDL書誌ID
- 024369426
-
- PubMed
- 23546005
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可